SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review

References

• Alsaadi JEA, Jones IM. Membrane binding proteins of coronaviruses. Future Virol. 2019;14(4):275–286.
   PubMed Web of Science ®Google Scholar
• Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(1):237–261.
   PubMed Web of Science ®Google Scholar
• Palacios Cruz M, Santos E, Velázquez Cervantes MA, et al. COVID-19, a worldwide public health emergency. Rev Clin Esp. 2020.S0014-2665:30092-8.
   PubMed Web of Science ®Google Scholar
• Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9:1.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Snijder EJ, Kikkert M, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO): COVID-19 dashboard [Internet]. 2020. [cited 2020 Apr 23]. Available from: https://covid19.who.int/.
   Google Scholar
• Al-Tawfig JA, Auwaerter PG. Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect. 2019;101(1):20–29.
   PubMed Web of Science ®Google Scholar
• Yang Y, Peng F, Wang R, et al. The deadly coronavirus: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.DOI:10.1016/j.jaut.2020.102434.
   Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist AC, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:1.
   PubMed Web of Science ®Google Scholar
• Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–286.
   PubMed Web of Science ®Google Scholar
• Conticini E, Frediani B, Caro D. Can atmospheric pollution be considered a Co-Factor in extremely high level of SARS-CoV-2 Lethality in Northern Italy? Environ Pollut. 2020 Apr 4. DOI:10.1016/j.envpol.2020.114465.
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko TP, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:3.
   Web of Science ®Google Scholar
• Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ Ritonavir,Darunavir/ Umifenovir,hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020 Apr 16. DOI:10.2174/0929867327666200416131117.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Wang N, et al., inventors; Univ Tsinghua, assignee. RBD (receptor binding domain) segment in MERS-CoV (Middle East respiratory syndrome coronavirus) membrane protein and coding gene and application thereof. China patent CN 103554235. 2014 Feb 05.
   Google Scholar
• Zhou Z, Feng Y, Zuo C, inventors; Sannuo-jiayi Biotechnology Co., Ltd., Beijing, assignee. A group of nucleotide sequence for anti infection of coronavirus and preventing SARS and application. China patent CN 1539967. 2004 Oct 27.
   Google Scholar
• Wang J, Liu J, inventors; Beijing Jinsaishi Antisense Nu, assignee. Antisense nucleic acid sequence for SARS coronavirus gene and its pharmaceutical use. China patent CN 1569873. 2005 Jan 26.
   Google Scholar
• Park H, Park S, Kim Y, inventors; Sungkyunkwan Univ Found for Corp Collab, assignee. Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus. United States patent US 20080207597. 2008 Aug 28.
   Google Scholar
• Hatakeyama S, Akiyama T, Kirikae T, et al., inventors; Kirin Brewery, Internat Medical Ct of Japan, Univ Kurume, assignee. Peptide binding to m (membrane) protein of SARS coronavirus and inhibiting binding of m protein to n (nucleocapsid) protein and system for analyzing interaction of m protein with n protein. Japan patent JP 2007129942. 2007 May 31.
   Google Scholar
• Liu YM, Lu PY, Tang QT, et al., inventors; Intradigm Corp, assignee. iRNA agents for anti-SARS coronavirus therapy. Canada patent CA 2523658. 2005 Mar 03.
   Google Scholar
• Qi Z, Pan X, inventors; No. 2 Military Medical Univ. PLA, assignee. Screening non-infective virus recombinant gene SARS-Cov-EGFP for medicine of anti SARS coronavirus. China patent CN 1454996. 2003 Nov 12.
   Google Scholar
• Chang H, Liao C, Cheng W, inventors; Healthbanks Biotech Co Ltd., assignee. Super-antigens derived from the SARS coronavirus E2 spike protein. European Patent patent EP 1749833. 2007 Feb 07.
   Google Scholar
• Cho EH, Chung SG, Myung HN, et al., inventors; Samjin Pharmaceutical Co., Ltd., assignee. Urea derivatives having strong antiviral effects on coronavirus, a process for the preparation thereof, and an antiviral composition containing the same for treating SARS. Republic of Korea patent KR 1020080020862. 2008 Mar 06.
   Google Scholar
• Chafekar A, Fielding BC. MERS-CoV: understanding the latest human coronavirus threat. Viruses. 2008;10:2.
   Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020 Feb 27. DOI:10.1016/j.apsb.2020.02.008
   Web of Science ®Google Scholar
• Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the Spotlight. Viruses. 2019;11:1.
   Web of Science ®Google Scholar
• Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020 [cited Mar 24].DOI:10.1001/jama.2020.4812.
   Web of Science ®Google Scholar
• De Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534.
   PubMed Web of Science ®Google Scholar
• Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397–412.
   PubMed Web of Science ®Google Scholar
• Babcook JS, Prabhakar BS, Coughlin M, inventors; Amgen Inc., assignee. Antibodies to SARS coronavirus. World Organization patent WO 2008060331. 2008 May 22.
   Google Scholar
• Leung KM, Feng DX, Pang SF, et al., inventors. Ultra Biotech Limited, The Regents of the Univ of California, assignee. Humanized monoclonal antibodies against SARS - associated coronavirus and treatment of patients with SARS. World Organization patent WO 2006095180. 2006 Sep 14.
   Google Scholar
• Zhao G, Zhou Y, Qiu H, et al., inventors; Inst of Microbiology and Epidemiology the Acad of Military Medical Sciences, assignee. Micromolecular antibody having neutralization activity for middle-east respiratory syndrome (MERS) coronavirus and application of micromolecular antibody. China patent CN 106380517. 2017 Feb 08.
   Google Scholar
• Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA. 2004;101(8):2536–2541.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479–490.
   PubMed Web of Science ®Google Scholar
• Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137.
   PubMed Web of Science ®Google Scholar
• Tan ELC, Stanton LW, inventors; Genome Institute of Singapore, assignee. Inhibition of SARS coronavirus infection with clinically approved antiviral drugs. United States patent US 2006153803. 2006 Jul 13.
   Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Deng X, StJohn SE, Osswald HL, et al. Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. J Virol. 2014;88(20):11886–11898.
   PubMed Web of Science ®Google Scholar
• Liu LL, inventor; Univ Beijing, assigne. 3CL protease inhibitor of non-peptide SARS coronavirus and use thereof. China patent CN 1965833. 2007 May 23.
   Google Scholar
• Yang H, Zhou K, Hu C, et al., inventors; Tianjin Joint Acad of Biomedicine, assignee. Application of acamprosate calcium in resistance to SARS (severe acute respiratory syndrome) coronavirus infection. China patent CN 108785293. 2018 Nov 13.
   Google Scholar
• Rao Z, Yang C, Lou Z, et al., inventors; Tianji international biomedicine joint research institute, assignee. Isatin-5-amide inhibiting agent with inhibition effect against SARS coronavirus main protease. China patent CN 103159665. 2013 Jun 19.
   Google Scholar
• Chen LR, Wang YC, Lin YW, et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett. 2005;15(12):3056–3062.
   Web of Science ®Google Scholar
• Zhang L, Song F, Dai H, et al., inventors; Inst Microbiology Cas, assignee. Use of asymmetric disulfide compound in SARS coronavirus infection resistance. China patent CN 106176728. 2016 Dec 07.
   Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
   PubMed Web of Science ®Google Scholar
• Wang L, Bao BB, Song GQ, et al. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study. Eur J Med Chem. 2017;137:450–461.
   PubMed Web of Science ®Google Scholar
• Fuhrman SA, Matthews DA, Patrick AK, et al., inventors; Pfizer Inc., assignee. Inhibitors of SARS related coronavirus proteinase. World Organization patent WO 2004093860. 2004 Nov 04.
   Google Scholar
• Kim DM, Ryu HJ, Thanh H, et al., inventors; Ind Found of Chonnan National Univ, assignee. Inhibitor of SARS-coronavirus 3CL protease activity and a method for screening the same. Republic of Korea patent KR 1020130002975. 2013 Jan 08.
   Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10.
   PubMed Web of Science ®Google Scholar
• Lin CW, Tsai FJ, Tsai CH, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68(1):36–42.
   PubMed Web of Science ®Google Scholar
• Keum YS, Jeong YJ, Yu MS, et al., inventors; Dongguk Univ Ind Acad Coop Found, assignee. Flavonoid which suppresses SARS coronavirus helicase and a pharmaceutically acceptable derivative and salt thereof, and a composition and a health functional food containing the same for treating or preventing SARS. Republic of Korea patent KR 1020130031551. 2013 Mar 29.
   Google Scholar
• Jeong YJYJ, Pyo SHSH, inventors; Kookmin Univ Ind Coop Found, assignee. Compound that inhibits MERS coronavirus helicase nsP13 and use thereof. Republic of Korea patent KR 1020190092776. 2019 Aug 08.
   Google Scholar
• Yu MS, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22(12):4049–4054.
   PubMed Web of Science ®Google Scholar
• Park HR, Yoon H, Kim MK, et al. Synthesis and Antiviral Evaluation of 7-ο-Arylmethylquercetin Derivatives against SARS-associated Coronavirus (SCV) and Hepatitis C Virus (HCV). Arch Pharm Res. 2012;35(1):77–85.
   PubMed Web of Science ®Google Scholar
• Lee C, Lee JM, Lee NR, et al. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase. Bioorg Med Chem Lett. 2009;19(6):1636–1638.
   PubMed Web of Science ®Google Scholar
• Yoohoon J, Yongjoo J, Chaewoon L, inventors; Konkut Univ Ind Coop Corp, assignee. SARS coronavirus helicase inhibitor or composition for suppressing SARS coronavirus containing aryl diketoacid derivative. Republic of Korea KR 1020100029528. 2010 Mar 17.
   Google Scholar
• Chong YH, Jeong YJ, Lee CW, inventors; Univ Yonsei Ind Acad Coop Found, assignee. Composition for inhibiting SARS coronavirus comprising aryl diketoacid derivatives. Republic of Korea patent KR 20100029528. 2010 Mar 17.
   Google Scholar
• Choi SD, Prasannavenkatesh, Shi HJ, et al., inventors; Univ Ajou Ind Academic Coop Found, assignee. Composition for preventing or treating middle east respiratory syndrome-coronavirus MERS-CoV infection. Republic of Korea patent KR 20180002504. 2018 Jan 08.
   Google Scholar
• Deng H, Ding M, Yuan K, inventors; Univ Beijing, assignee. Polypeptide drug for inhibiting SARS coronavirus from infecting host cell. China patent CN 1566142. 2005 Jan 19.
   Google Scholar
• Kim H, Ham DS, Kwon T, et al., inventors. SK Chemicals Co. Ltd., assignee. S Immunogenic Middle East Respiratory Syndrome Coronavirus MERS-CoV S protein composition and producing method thereof. Republic of Korea patent KR 20180058206. 2018 May 31.
   Google Scholar
• Xu X, Deng H, Lironget C, inventors; Univ Beijing, assignee. Active constituent of traditional Chinese medicine capable of inhibiting SARS coronavirus infection and its bioactivity measuring method. China patent CN 1602853. 2005 Apr 06.
   Google Scholar
• Zheng B, Guan Y, Huang J, et al., inventors; The University of Hong Kong, assignee. Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof. United States patent US 20060110758. 2006 May 25.
   Google Scholar
• Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661.
   PubMed Web of Science ®Google Scholar
• Li SY, Chen S, Zhang HQ, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005;67(1):18–23.
   PubMed Web of Science ®Google Scholar
• Yang Y, Islam MS, Wang J, et al. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci. 2020;16(10):1707–1717.
   Web of Science ®Google Scholar
• Wan S, Xiang Y, Fang W, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. J Med Virol. 2020 [cited Mar 21].DOI:10.1002/jmv.25783
   Web of Science ®Google Scholar
• Zhang DH, Wu KL, Zhang X, et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med. 2020;18(2):152–158.
   PubMed Web of Science ®Google Scholar
• Tokutake S, Katayama H, Yoshinaka Y, et al., inventors; Kikkoman Corp, assignee. Anti-SARS coronavirus agent. Japan patent JP 2005314316. 2005 Nov 10.
   Google Scholar
• Chang G, Luo H, Luo H, et al., inventors; institute of disease prevention and control academy of military medical sciences, assignee. Broad-spectrum viral infection inhibitor. World Organization Patent WO 2017124831. 2017 Jul 27.
   Google Scholar
• Li H, Xia N, Hasselwander S, et al. Resveratrol and vascular function. Int J Mol Sci. 2019;20:9.
   Google Scholar
• Lin SC, Ho CT, Chuo WH, et al. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis. 2017;17(1):144.
   PubMedGoogle Scholar
• Pezzuto JM. Resveratrol: twenty years of growth, development and controversy. Biomol Ther (Seoul). 2019;27(1):1–14.
   PubMed Web of Science ®Google Scholar
• Yuen KY, Chen F, Chan KH, et al., inventors; The University of Hong Kong, assignee. Baicalin and its derivative as a treatment for SARS coronavirus infection or other related infections. United States patent US 2005215494. 2005 Sep 29.
   Google Scholar
• Yi Y, Lin H, Yao X, inventors; Univ Pla 2nd Military Medical, assignee. Use of total bryostatin for preparing medicine for anti SARS coronavirus. China patent CN 1454593. 2003 Nov 12.
   Google Scholar
• Anantpadma M, Lane T, Zorn KM, et al. Ebola virus bayesin machine learning models enable new in Vitro leads. ACS Omega. 2019;4(1):2353–2361.
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868.
   PubMed Web of Science ®Google Scholar
• Xu F, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–460.
   PubMed Web of Science ®Google Scholar
• Nishiura H, Linton NM, Akhmetzhanov AR. Initial cluster of novel coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission. J Clin Med. 2020;9:2.
   Web of Science ®Google Scholar
• Smith N, Fraser M. Straining the System: novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters. Am J Public Health. 2020;110(5):648–649.
   PubMed Web of Science ®Google Scholar
• Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. BioRxiv. 2020 [cited Feb 11].DOI:10.1101/2020.02.07.937862
   Google Scholar
• Sisk JM, Frieman MB. Screening of FDA-approved drug for treatment of emerging pathogens. ACS Infect Dis. 2015;1(9):401–402.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
   PubMed Web of Science ®Google Scholar
• Lane TR, Comer JE, Freiberg NA, et al. Repurposing Quinacrine against Ebola Virus Infection in vivo. Antimicrob Agents Chemother. 2019;63:9.
   Web of Science ®Google Scholar
• Furuyama W, Marzi A. Ebola Virus: pathogenesis and Countermeasure Development. Annu Rev Virol. 2019;6(1):435–458.
   PubMedGoogle Scholar
• Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola Virus disease therapeutics. N Engl J Med. 2019;31(24):2293–2303.
   Google Scholar
• Ekins S, Southan C, Coffee M. Finding small molecules for the ‘next Ebola’. F1000Res. 2015;4:58.
   Google Scholar
• Food & Drug Administration [Internet]. United States (US): first FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. 2019 [cited 2020 Apr 23]. Available from: https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health.
   Google Scholar
• Virological.org [Internet]. São Paulo (Brazil): first cases of coronavirus disease (COVID-19) in Brazil, South America. 2020 [cited 2020 Apr 23]. Available from: http://virological.org/t/first-cases-of-coronavirus-disease-covid-19-in-brazil-south-america-2-genomes-3rd-march-2020/409.
   Google Scholar
• Liu L, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92(5):491–494.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893.
   PubMed Web of Science ®Google Scholar
• Dyall J, Gross R, Kindrachuk J, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs. 2017;77(18):1935–1966.
   PubMedGoogle Scholar
• Yuan S. Statins May decrease the fatality rate of Middle East respiratory syndrome infection. mBio. 2015;6:4.
   Web of Science ®Google Scholar
• Galasiti Kankanamalage AC, Kim Y, Damalanka VC, et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem. 2018;150:334–346.
   PubMed Web of Science ®Google Scholar
• De Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12):6771–6776.
   PubMed Web of Science ®Google Scholar
• Momattin H, Al-Ali AY, Al-Tawfig JA. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis. 2019;30:9–18.
   PubMed Web of Science ®Google Scholar
• Chou CY, Chang HC, Hsu WC, et al. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry. 2004;43(47):14958–14970.
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature. 2007;448(7154):645–646.
   PubMed Web of Science ®Google Scholar
• Zhang H, Saravanan KM, Yang Y, et al. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCoV. Preprints. 2020 [accessed Apr 25]; [https://www.preprints.org/manuscript/202002.0061/v1] DOI:10.20944/preprints202002.0061.v1
   Google Scholar
• Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020;35:6.
   Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Li H, Wang YM, Xu JY. et al. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He Hu Xi Za Zhi. 2020;43(3):170–172.
   PubMedGoogle Scholar
• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.
   PubMed Web of Science ®Google Scholar
• Andrade CH, Neves BJ, Melo-Filho CC, et al. In Silico CHEMOGENOMICS DRUG REPOSITIONING STRATEGIES FOR NEGLECTED TROPICAL DISEASES. Curr Med Chem. 2019;26(23):4355–4379.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TYY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Pasaoglu I, Onmez FE. Macular toxicity after short-term hydroxychloroquine therapy. Indian J Ophthalmol. 2019;67(2):289–292.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogué B, Leroux G. et al. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. Clin Ver Allergy Immunol. 2015;49(3):317–326.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med. 2020 May 2. DOI:10.1111/acem.14005.
   PubMedGoogle Scholar